Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger

OBJECTIVE: To assess long‐term efficacy and safety of canakinumab and the response to vaccination in children ages ≤5 years with cryopyrin‐associated periodic syndrome (CAPS). METHODS: CAPS patients (ages ≤5 years) received 2 mg/kg canakinumab subcutaneously every 8 weeks; patients with neonatal‐ons...

Descripción completa

Detalles Bibliográficos
Autores principales: Brogan, Paul A., Hofer, Michael, Kuemmerle‐Deschner, Jasmin B., Koné‐Paut, Isabelle, Roesler, Joachim, Kallinich, Tilmann, Horneff, Gerd, Calvo Penadés, Inmaculada, Sevilla‐Perez, Belén, Goffin, Laurence, Lauwerys, Bernard R., Lachmann, Helen J., Uziel, Yosef, Wei, Xiaoling, Laxer, Ronald M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Pediatric Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899890/
https://www.ncbi.nlm.nih.gov/pubmed/31161734
http://dx.doi.org/10.1002/art.41004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899890/
https://www.ncbi.nlm.nih.gov/pubmed/31161734
http://dx.doi.org/10.1002/art.41004

Ejemplares similares